A dysregulated interleukin-18–interferon-γ–CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis

Efficacy and Safety of Canakinumab in sJIA Patients with and without Fever at Baseline: Results from an Open‐label, Active Treatment Extension Study

(2020) Hermine I Brunner et al.   Arthritis & Rheumatology

IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome

(2019) Shima Yasin et al.   RHEUMATOLOGY

IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome

(2019) Shima Yasin et al.   RHEUMATOLOGY

Innately adaptive or truly autoimmune

(2019) Christoph Kessel et al.   Arthritis & Rheumatology

Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis

(2019) Pui Y Lee et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome

(2018) Eric S. Weiss et al.   BLOOD

Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany

(2018) Claas H. Hinze et al.   Pediatric Rheumatology

Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis

(2017) Christoph Kessel et al.   Arthritis & Rheumatology

Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

(2016) Claudia Bracaglia et al.   ANNALS OF THE RHEUMATIC DISEASES

Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ

(2015) Karen Put et al.   RHEUMATOLOGY

2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C

(2015) Sarah Ringold et al.   ARTHRITIS AND RHEUMATISM

Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?

(2014) Peter A. Nigrovic   Arthritis & Rheumatology

The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness

(2012) Keith A. Sikora et al.   ARTHRITIS AND RHEUMATISM

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

(2012) Nicolino Ruperto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

CXCR3 ligands: redundant, collaborative and antagonistic functions

(2011) Joanna R Groom et al.   IMMUNOLOGY AND CELL BIOLOGY

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

(2011) Elizabeth D. Mellins et al.   Nature Reviews Rheumatology

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis

(2010) M. Shimizu et al.   RHEUMATOLOGY

The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis

(2009) Michael Frosch et al.   ARTHRITIS AND RHEUMATISM

Defective phosphorylation of interleukin-18 receptor β causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis

(2009) Wilco de Jager et al.   ARTHRITIS AND RHEUMATISM

Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays

(2009) Wilco de Jager et al.   BMC IMMUNOLOGY

S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin

(2008) Helmut Wittkowski et al.   ARTHRITIS AND RHEUMATISM

The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

(2008) Marco Gattorno et al.   ARTHRITIS AND RHEUMATISM